# Junya Fujimoto

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/junya-fujimoto/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,773 |
| Field | Radiomics and Machine Learning in Medical Imaging |
| h-index | 82 |
| i10-index | 173 |
| OpenAlex ID | https://openalex.org/A5082372978 |
| ORCID iD | https://orcid.org/0000-0003-4813-3163 |
| Works | 706 |

## Researcher papers

- [Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing](https://scholariq.org/papers/intratumor-heterogeneity-in-localized-lung-adenocarcinomas-delineated-by/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer](https://scholariq.org/papers/targeting-dna-damage-response-promotes-antitumor-immunity-through-sting-mediated/)
- [A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer](https://scholariq.org/papers/a-prospective-multi-institutional-pathologist-based-assessment-of-4/)
- [Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial](https://scholariq.org/papers/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-operable-non-small-cell/)
- [Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1](https://scholariq.org/papers/proteomic-profiling-identifies-dysregulated-pathways-in-small-cell-lung-cancer/)
- [Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer](https://scholariq.org/papers/randomized-double-blind-phase-ii-study-of-temozolomide-in-combination-with/)
- [Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer](https://scholariq.org/papers/single-cell-analyses-reveal-increased-intratumoral-heterogeneity-after-the-onset/)

## Researcher topics

- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [AI in cancer detection](https://scholariq.org/topics/ai-in-cancer-detection/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.